This is a US news story, published by Sky News, that relates primarily to NHS news.
For more US news, you can click here:
more US newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Sky News, you can click here:
more news from Sky NewsOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
drug lecanemab. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest lecanemab news, medicines regulator news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
mild AlzheimerSky News
•
72% Informative
Lecanemab can slow the decline in memory and mental agility by 27% in patients with mild Alzheimer's.
But a separate NHS watchdog has ruled it's not cost-effective and won't be available.
Decision means the first drug to show an effect in Alzheimer's will only be available privately.
In the US the treatment costs 20,000 a year.
VR Score
77
Informative language
81
Neutral language
25
Article tone
semi-formal
Language
English
Language complexity
59
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links